A2B5 Expression in Central Nervous System and Gliomas

Dominique Figarella-Branger (1) , Carole Colin (1) , Nathalie Baeza-Kallee (1) , Aurélie Tchoghandjian (1)

1 INP - Institut de neurophysiopathologie

A2B5 IgM recognizes c-series gangliosides with three sialic acids. The aim of this review was to focus on A2B5 expression in the central nervous system and gliomas. In brain development, A2B5+ cells are recorded in areas containing multipotent neural stem cells (NSC). In adults, A2B5+ cells persist in neurogenic areas and in white matter where it identifies oligodendrocyte precursor cells (OPCs) but also cells with NSC properties. Although the expression of A2B5 has been widely studied in culture, where it characterizes bipotential glial progenitor cells, its expression in vivo is less characterized mainly because of technical issues. A new interest was given to the NSCs and OPCs since the discovery of cancer stem cells (CSC) in gliomas. Among other cell surface molecules, A2B5 has been identified as an accurate marker to identify glioma CSCs. We and others have shown that all types of gliomas express A2B5, and that only A2B5+ cells, and not A2B5- cells, can generate a tumor after orthotopic implantation in immunocompromised animals. Moreover, A2B5 epitope expression is positively correlated with stemness and tumor growth. This review highlights that A2B5 is an attractive target to tackle glioma CSCs, and a better characterization of its expression in the developing and adult CNS will benefit to a better understanding of gliomagenesis.

Mots clés: A2B5 IgM; cancer stem cell; central nervous system; ganglioside; glioma

Domaines: Sciences du Vivant [q-bio]; Cancer

Dominique Figarella-Branger, Carole Colin, Nathalie Baeza-Kallee, Aurélie Tchoghandjian. A2B5 Expression in Central Nervous System and Gliomas. International Journal of Molecular Sciences, 2022, 23 (9), pp.4670. ⟨10.3390/ijms23094670⟩. ⟨hal-03981898⟩